Overview

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Status:
Terminated

Trial end date:
2018-03-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent cytotoxic chemotherapy in patients with EGFR-mutated, advanced/metastatic NSCLC after failure of at least 1 previous EGFR-directed TKI and at least 1 line of platinum-containing doublet chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Clovis Oncology, Inc.

Treatments:

Albumin-Bound Paclitaxel
Docetaxel
Gemcitabine
Paclitaxel
Pemetrexed